All In Biotech

Drug Trial Radar · NCT04896632

Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants

A Randomized, Participant- and Investigator-blinded, Placebo-controlled, Single Ascending Dose and Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

64

Actual

Start

May 13, 2021

Primary completion

Nov 24, 2022

Study completion Nov 24, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single ascending doses and multiple doses of INE963 given orally in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

  • INE 963Drug

    Part A: Single ascending dose with 7 planned cohorts\> Part B: multiple dose with 2 planned cohort q24x3 days

  • PlaceboOther

    Part A: single ascending dose with 7 planned cohorts. Part B: multiple dose with 2 planned q24x3 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects with Significant Clinical Safety Labs, reporting SAEs and AEs and ECG findingsTime frame: Dose escalation (21 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Mere Way, Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.